Skip to content
HowShorted

Emergent Biosolutions, Inc. short interest in 2018

In 2018, Emergent Biosolutions, Inc.'s disclosed short interest ran from 2.93% of shares outstanding on 12 Jan 2018 to 4.57% on 31 Dec 2018, a change of +1.64 percentage points. The year's high was 5.18% on 13 Apr 2018 and its low 2.80% on 31 Jan 2018, averaging 3.87% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.26 days on 30 Apr 2018. Full history: Emergent Biosolutions, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Emergent Biosolutions, Inc. in 2018

2018 in figures

Start of year
2.93% (12 Jan 2018)
End of year
4.57% (31 Dec 2018)
Change
+1.64 pp
High
5.18% (13 Apr 2018)
Low
2.80% (31 Jan 2018)
Average
3.87%
Highest days to cover
9.26 (30 Apr 2018)
SEC filings marked
10

Every report in 2018

Emergent Biosolutions, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20182.93%3.57results (8-K)
31 Jan 20182.80%3.77results (8-K)
15 Feb 20183.02%3.37
28 Feb 20183.36%3.38results (8-K), 10-K filed
15 Mar 20183.23%3.16
29 Mar 20184.42%3.81
13 Apr 20185.18%7.45
30 Apr 20184.34%9.26
15 May 20183.70%5.21results (8-K), 10-Q filed
31 May 20183.67%7.12
15 Jun 20184.16%6.54
29 Jun 20184.66%4.85
13 Jul 20184.21%7.76
31 Jul 20183.69%7.57
15 Aug 20183.60%6.98results (8-K), 10-Q filed
31 Aug 20183.28%6.15
14 Sep 20183.20%3.90
28 Sep 20183.98%3.67
15 Oct 20183.88%5.89
31 Oct 20183.52%6.03
15 Nov 20184.40%5.31results (8-K), 10-Q filed
30 Nov 20184.83%7.00
14 Dec 20184.22%4.57
31 Dec 20184.57%4.32

See also: Emergent Biosolutions, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.